Effect of Long-Chain n-3 Polyunsaturated Fatty Acid on Inflammation Mediators During Osteoblastogenesis
- 1 March 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Medicinal Food
- Vol. 11 (1), 105-110
- https://doi.org/10.1089/jmf.2007.540
Abstract
This study examined the effects of eicosapentaenoic acid (EPA) and arachidonic acid (AA) on inflammation mediators during osteoblastogenesis, in terms of modulation of the cyclooxygenase (COX)-2 and the inducible nitric oxide (NO) synthase (iNOS) pathways. We hypothesized that n-3 polyunsaturated fatty acid (PUFA) would reduce the production of inflammation mediators, including prostaglandin E2 (PGE2) and NO, and related mRNA gene expression during osteoblastogenesis. Mouse bone marrow stromal cells (ST-2) were treated with 40 μM ethanol (as a control), 40 μM AA, or 40 μM EPA in osteogenic medium for 7, 14, 21, or 28 days. Prior to harvest, cells were treated with respective treatments along with cytokine mixtures for an additional 24 hours, and then cells were harvested for mRNA expression. In addition, cells were also treated with respective treatments along with the same cytokine mixtures for an additional 48 hours for experiment measuring PGE2 and NO production using conditioned culture medium and protein expression using cells. Except for 7 days of culture, AA treatment resulted in the highest value for PGE2 production throughout 28 days of culture. AA treatment also enhanced COX-2 mRNA expression up to 21 days. AA treatment resulted in a higher value for NO production after 7 days, while EPA treatment yielded a higher value for NO production relative to those receiving AA treatment after 14 and 21 days. Our investigation has corroborated that the protective action of EPA on osteoblastogensis was mediated by the modulation of PGE2 and the NO pathway.Keywords
This publication has 30 references indexed in Scilit:
- OsteoimmunologyInternational Archives of Allergy and Immunology, 2006
- Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): A rose by any other name…Cytokine & Growth Factor Reviews, 2006
- Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseasesArthritis Care & Research, 2006
- Prostaglandin E2 Strongly Inhibits Human Osteoclast FormationEndocrinology, 2005
- Pathogenesis of osteoporosis: concepts, conflicts, and prospectsJCI Insight, 2005
- Prostaglandin E2 Receptors EP2 and EP4 Are Down-regulated during Differentiation of Mouse Osteoclasts from Their PrecursorsPublished by Elsevier BV ,2005
- Role of cyclooxygenase-2 in bone resorption.Journal of UOEH, 2003
- Osteoporosis Prevention, Diagnosis, and TherapyJama-Journal Of The American Medical Association, 2001
- Nitric oxide: A cytokine-induced regulator of bone resorptionJournal of Bone and Mineral Research, 1995
- Journal of Bone and Mineral ResearchJournal of Bone and Mineral Research, 1993